Diabetes Technol Ther:挑战指南!并不是所有的高分化型甲状腺癌儿童患者均要接受全甲状腺切除

2016-11-29 MedSci MedSci原创

目前的指南建议高分化型甲状腺癌(WDTC)儿童患者应行甲状腺全切除术。然而,这些指南是在现有高分辨率成像技术之前所制定的。本研究推测应有部分儿童患者或可经腺叶切除术而得到完全治愈。采用回顾性分析设计,纳入2004年至2015年接受治疗的73名WDTC儿童患者。我们采用了两种不同的风险分层标准。首先研究人员确定符合ATA“低风险”标准的患者数量,定义为疾病分期为N0 / NX或偶然的N1a。然后,研

目前的指南建议高分化型甲状腺癌(WDTC)儿童患者应行甲状腺全切除术。然而,这些指南是在现有高分辨率成像技术之前所制定的。本研究推测应有部分儿童患者或可经腺叶切除术而得到完全治愈。

采用回顾性分析设计,纳入2004年至2015年接受治疗的73名WDTC儿童患者。

我们采用了两种不同的风险分层标准。首先研究人员确定符合ATA“低风险”标准的患者数量,定义为疾病分期为N0 / NX或偶然的N1a。然后,研究人员确定了一套“低风险”的组织病理学标准,包括单发肿瘤≤4cm,没有预定义的高危因素,确定符合这些标准的患者的比例。

最终研究纳入27名(37%)男性和46名(63%)女性,平均年龄为13.4岁。同侧和对侧多灶性病灶分别有27名(37%)和19名(26%)患者。37名(51%)的患者有淋巴结转移(N1a=18/N1b=19)。术前超声确定了所有存在淋巴结疾病的患者。73名患者中,39名(53.4%)患者符合ATA 低风险标准,16名(21.9%)符合非常低风险的标准。所有的非常低风险的患者在初步治疗后均表现出良好的反应,在平均随访36.4个月后,无持久性/复发。

总而言之,超声和组织病理学确定了可能受益于叶切除术的患者人群,从而避免了与全甲状腺切除术相关的风险,以及潜在的医疗和社会心理问题的发生。研究人员构建了一个临床框架,以刺激讨论将叶切除术作为低风险患者治疗的一个选择。

原始出处:

Polonsky WH, et al. Is it time to reconsider lobectomy in low-risk paediatric thyroid cancer?  Diabetes Technol Ther. 2016.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2017-08-10 gds2009
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2017-03-07 shock_melon
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2016-12-01 xiaotaiyang1

    了解一下

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2016-11-30 尹玉伟

    这个可以

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2016-11-30 博雷

    儿童甲状腺癌

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1759824, encodeId=08571e5982454, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Wed Aug 30 11:40:00 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901509, encodeId=1ff71901509aa, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Dec 01 21:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637555, encodeId=9fa9163e555d2, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Oct 17 03:40:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952989, encodeId=dfc51952989bd, content=<a href='/topic/show?id=d2b010220055' target=_blank style='color:#2F92EE;'>#高分化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102200, encryptionId=d2b010220055, topicName=高分化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Thu Aug 10 03:40:00 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652174, encodeId=703d16521e43e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Mar 07 19:40:00 CST 2017, time=2017-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31525, encryptionId=286c31525bd, topicName=分化型甲状腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Thu Dec 01 13:40:00 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159371, encodeId=bd121593e136, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Thu Dec 01 11:00:02 CST 2016, time=2016-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159167, encodeId=373715916eb7, content=这个可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCSvgHPvuQp0g9YLQuk8Dv2tO2J8cA1nBOPWOR46Rv1IMw309iaVI4zibSE52MibbXtA54h46besGYv6vpQfsUHpY9TaCKOVRmm2A/0, createdBy=14511949364, createdName=尹玉伟, createdTime=Wed Nov 30 12:10:43 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159131, encodeId=dde315913193, content=儿童甲状腺癌, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/6D9C89AB36A71EA450A5729452654834/100, createdBy=b07f1943308, createdName=博雷, createdTime=Wed Nov 30 09:38:11 CST 2016, time=2016-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159127, encodeId=9d6815912e44, content=非常精彩!, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76491981781, createdName=1e184d7bm65(暂无匿称), createdTime=Wed Nov 30 09:07:51 CST 2016, time=2016-11-30, status=1, ipAttribution=)]
    2016-11-30 1e184d7bm65(暂无匿称)

    非常精彩!

    0

相关资讯

盘点:近期甲状腺癌研究汇总

甲状腺癌虽然是一种恶性肿瘤,但是大多数情况下其危害性并不高,可能存在的唯一症状是焦虑,而这种症状甚至不能成为临床诊断的依据。很大比例的患者被实施了甲状腺切除手术、淋巴结切除或放射性治疗,这实际上可能是没有必要的。根据8月17号发表在《新英格兰医学杂志》上一组癌症登记数据,在过去的一年中,有超过六万名美国成年人被诊断为甲状腺癌。在这个庞大的数字中,因过度诊断被误诊的人数占了不少的一部分。也已经有

盘点:二甲双胍,能否成为“抗癌卫士”?

二甲双胍是治疗糖尿病的“明星”药物;但二甲双胍的“野心”还不止于此,它能成为新一代的“抗癌卫士”吗? 【1】二甲双胍还可以治疗胰腺癌? 研究纳入了1916名PDAC患者,在诊断腺癌前存在DM,且使用降糖药1年以上。其中1098例(57.3%)使用二甲双胍治疗,818例(42.7%)使用其他降糖药治疗。 二甲双胍与非二甲双胍组相比,平均生存分别为5.5个月和4.2个月(P<

J Clin Endocrinol Metab:绝经后女性行子宫切除术可增加甲状腺癌的发病风险

已知雌激素是甲状腺癌发病的一个危险因素。本研究旨在子宫切除术、双侧输卵管卵巢切除术(BSO)与甲状腺癌发病率之间的关联。 采用前瞻性队列研究,纳入美国40个临床中心的127566名参与女性健康计划(1993-1998年)的研究对象,年龄在50-79岁。 主要研究结果为子宫切除术和BSO,使用医疗记录审查证实甲状腺癌病例。 结果,平均随访14.4年后,共发生了344例甲状腺癌病例。

甲状腺癌,不要再过度诊断了!

“至少50万甲状腺癌患者存在过度诊断,大多数女性患者都接受了不必要的外科切除和抗癌治疗!”根据8月17号发表在《新英格兰医学杂志》上一组癌症登记数据,IARC的研究者如是说。至少50万甲状腺癌患者存在过度诊断!这是一组来自12个高收入国家(澳大利亚、丹麦、英格兰、芬兰、发过、意大利、日本、挪威、南韩、苏格兰、瑞典、美国)1987~2007年的癌症登记数据,一共评估了47万名女性和9万名男性。多数患

甲状腺癌或被过度诊断

一项在新英格兰医学杂志上的文章称,在过去的一年中,有超过六万名美国成年人被诊断为甲状腺癌。在这个庞大的数字中,因过度诊断被误诊的人数占了不少的一部分。也已经有不少人的生活因为这样的过度诊断而发生变化。这项调查涉及12个不同的国家和地区。结果显示,自1987年到2007年,一共有超过47万女性和9万男性被过度诊断为甲状腺癌。这些可能归因于过度的医疗检测和未经证实的新诊断手段。这些手段包括CT和MRI